Plasminogen activator inhibitor type 1 (PAI-1) correlates with the risk and progression of systemic lupus erythematosus (SLE). We aimed to assess the relationship between the PAI-1 4G/5G gene polymorphism and SLE/lupus nephritis risk. We identified the eligible studies regarding the association between the PAI-1 4G/5G gene polymorphism and the risk of SLE/lupus nephritis. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a fixed-effects model or, in the presence of heterogeneity, a random-effects model. A total of six studies were enrolled in our pooled analysis. The PAI-1 4G/5G gene polymorphism had no significant association with the risk of SLE among overall populations, Asians and Caucasians. Nor was it associated with susceptibility to lupus nephritis among overall populations, Asians and Caucasians. Sensitivity analysis yielded similar results. No marked publication bias was noted. In conclusion, the PAI-1 4G/5G gene polymorphism is not associated with susceptibility to SLE/lupus nephritis among overall populations, Asians and Caucasians. However, more studies should be conducted in the future.

中文翻译：

---

PAI-1 4G / 5G基因多态性与系统性红斑狼疮/狼疮性肾炎的风险之间的关联。

纤溶酶原激活物抑制剂1型（PAI-1）与系统性红斑狼疮（SLE）的风险和进展相关。我们旨在评估PAI-1 4G / 5G基因多态性与SLE /狼疮肾炎风险之间的关系。我们确定了有关PAI-1 4G / 5G基因多态性与SLE /狼疮性肾炎风险之间关系的合格研究。使用固定效应模型或在存在异质性的情况下使用随机效应模型计算比值比（OR）和95％置信区间（CI）。我们的汇总分析共纳入了六项研究。PAI-1 4G / 5G基因多态性与总体人群，亚洲人和高加索人中SLE的风险没有显着相关性。它与总体人群，亚洲人和高加索人对狼疮性肾炎的易感性也不相关。敏感性分析得出相似的结果。没有发现明显的出版偏见。总之，在亚洲人和高加索人群中，PAI-1 4G / 5G基因多态性与SLE /狼疮肾炎的易感性无关。但是，将来应该进行更多的研究。